Spinal Cord Injury Neuroprotection With Glyburide

Drug

General health

Online since 1 November 2022, updated 830 days ago

About this trial

This trial is enrolling individuals with acute cervical or thoracic spinal cord injuries to test the feasibility, safety and efficacy of a drug (Glyburide/DiaBeta). Investigators want to see if they can recruit participants within 8 hours of spinal cord injury (in preparation for a larger study), assess drug safety and determine if drug can help lessen further damage (neuroprotection) following acute spinal cord injury. If included, participants will receive 12 oral doses of Glyburide (every 6 hours) over 3 days starting within 8 hours of spinal cord injury. Final testing will be performed after 1 year.

Included participants

Gender

All

Age

18 - 80 years

Injury level

C2 - T12

Severity (AIS)?

AIS-A

AIS-B

AIS-C

Time since injury

≤ 8 null

Injury type

Traumatic

Healthy volunteers

Yes

C2-T12

What’s involved

Type

Drug

Details

- participants will receive 12 doses of Glyburide over 3 days (every 6 hours) - the total daily dose of Glyburide will be 3.125mg on day 1 and 2.5mg on days 2 and 3 - Final testing of neurological function will be performed after 1 year

Potential benefits

Main benefits

General health

Additional benefits

Arm/hand function

Sensory function

Standing/walking/mobility

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results